Legal Basis: Ley 16.463 and the Argentine Regulatory Hierarchy

1. Key takeaways

The legal hierarchy governing medical devices in Argentina runs as follows: Ley 16.463 (the National Health Products Act) is the parent act → Decreto 1490/92 establishes ANMAT and defines its responsibilities → the individual ANMAT Disposiciones are the operative norms → MERCOSUR resolutions, once transposed into domestic law, are incorporated into this hierarchy.

The basis for administrative and criminal liability of companies in regulatory matters rests mainly on Ley 16.463 and Decreto 341/92; liability for untruthful content in sworn declarations is pursued separately under Article 110 of Decreto 1759/72. Understanding this hierarchy is the benchmark for judging whether a given ANMAT document is an administrative regulation or a law, and therefore what weight it carries in a dispute, in enforcement, or in a court proceeding.

For compliance planning, the hierarchy matters in a very concrete way. Operative disposiciones can be amended or replaced quickly by the agency, while the parent act and the decrees form a stable floor of authorization, penalty and due-process rules that does not move with each new regulation. A company that knows which layer each obligation comes from can predict how stable that obligation is and how much documentation effort is justified in defending it.

2. Legal basis

The instruments below span three layers of the hierarchy — the parent act, the founding and procedural decrees, and the current operative provisions on notification-based market entry for lower-risk products.

3. Expert insights

Insight one: Ley 16.463 is a law of 1964 that remains the liability foundation of Argentine health product regulation to this day. Its value lies not in technical provisions but in the fact that it defines the unauthorized manufacture, sale and import of health products as punishable conduct, and it authorizes the administration to take measures such as bans on sale and seizure. Every Disposición issued by ANMAT ultimately traces its enforceability back to this act. That is why a regulation that looks purely technical still carries the force of a sixty-year-old statute behind it.

Insight two: Decreto 341/92 is the procedural basis for precautionary measures. Unlike ordinary administrative sanctions, precautionary measures can be implemented before an investigation is completed — bans on sale, suspension of registrations and market withdrawals are often based on this decree. For companies, this means that a single reported suspicion of non-compliance can affect sales before any conclusion has been reached. The practical implication is that the quality of day-to-day compliance documentation determines how credibly a company can argue against a precautionary measure when it arrives without warning.

Insight three: Disposición ANMAT 236/2026 expressly points the consequences of violations to both Ley 16.463 and Ley 18.284. This is a notable detail in the 2026 new rule: the legislator did not create a new penalty regime but invoked the existing laws. It signals that while Argentina loosens front-end market access, it deliberately preserves the original intensity of enforcement. Companies entering through the lighter notification pathway should not read the simplified procedure as a reduction in substantive liability.

4. Practical recommendations

1. Build a three-tier document ledger covering law — regulation — operational guidance. In internal compliance files, keep Ley 16.463, Decreto 341/92 and the specific Disposiciones archived separately, so that the basis of liability can be located quickly in a dispute scenario.
2. Integrate Article 110 of Decreto 1759/72 into the risk notice of your signing process. For every sworn declaration that requires the signature of a legal representative or a technical responsible person, the facts should be verified and the verification archived before signing, so that a procedural signature never turns into substantive liability.
3. Pre-set precautionary measure scenarios in the emergency plan. Specify in advance who handles delisting, who handles customer communication and who prepares the appeal materials once an ANMAT ban or suspension notice is received, so the response can be launched within 48 hours.
4. Track whether ANMAT issues supplementary penalty rules for specific Disposiciones, in particular the first enforcement cases after 236/2026 enters into force; these can serve as a practical reference for the real compliance yardstick applied by the authority.

5. Verification checklist

• □ Confirmed that Ley 16.463 is the parent act and Decreto 1490/92 the basis for the establishment of the agency
• □ Mapped the types of precautionary measures available under Decreto 341/92
• □ Integrated Article 110 of Decreto 1759/72 into the internal signing risk notice
• □ Confirmed that 236/2026 invokes Ley 16.463 and Ley 18.284 for violations
• □ Built the three-tier regulation ledger and designated an owner for its maintenance
• □ Prepared an emergency response process for ban or suspension notices

Regulatory information verified as of October 29, 2026.

In Argentina, GRZAN operates a wholly owned subsidiary that can act as the registration holder and importer for foreign manufacturers, directly undertaking classification determination, pathway selection, GMP and CFS documentation chains, Spanish-language localization of technical documentation and labels, HELENA submissions and deficiency responses, as well as BONITA import notifications, operation of the ARGOS vigilance system, change maintenance and 5-year renewal planning.

The GRZAN regulatory team consists of professionals with many years of hands-on international registration experience and continuously tracks the developments of regulatory authorities worldwide; all published content follows the editorial standard of conclusions first, traceable bases and verifiable figures. For a tailored market access plan for Argentina or the MERCOSUR region covering a specific product, contact the GRZAN regulatory team at info@grzanglobal.com.